Clinical trials: Nivolumab
Melanoma, Healthy Volunteers
Polish Microbiome Map
Knowledge about the correlations between the composition of the gut microbiome and a wide range of diseases has substantially increased in recent years.
- Conditions
- Melanoma, Healthy Volunteers, Microbiome, Metagenome
- Trial name
- NCT04169867
- Testing
- Collection of stool samples
- Where
- Poland
- Volunteers
- 1,160 people, healthy volunteers welcome
- Sponsor
- Ardigen
Cancer, Immune System Disorder
Montreal Immune-Related Adverse Events (MIRAE) Study
Immune checkpoint inhibitors (ICI) are among the most promising approaches to fighting cancer. However, a substantial percentage of patients experience off-target adverse effects in the form of mild to severe inflammation in…
- Conditions
- Cancer, Immune System Disorder, Inflammatory Reaction, Autoimmune Diseases
- Trial name
- MIRAE (NCT05139706)
- Where
- Canada
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
Non Small Cell Lung Cancer
Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLC
Subjects will be eligible for this study if they are about to start on a drug called nivolumab for lung cancer. Some patients' cancers respond to nivolumab but a majority of patients do not.
- Trial name
- NO3DEXPL (NCT03371992)
- Testing
- Nivolumab, 3D-EX, Evaluation of Response by RECIST
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Nilogen Oncosystems
Lung Cancer
A Study of Participants With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment by Lung Initiative on Sequence Therapy
The purpose of this trial is to describe the following, for each cohort, in real world conditions in France: The characteristics and treatment sequence of patients treated with nivolumab The effectiveness of nivolumab treatment…
- Trial name
- LIST (NCT04500535)
- Where
- France
- Volunteers
- 535 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
HNSCC
WGA in Platinum-refractory HNSCC Underwent Nivolumab
To choose a subgroup who could clearly benefit from Nivolumab, we are proposing a prospective observational study. Whole-genome study (WGS) analysis will be performed on archived cancer tissues from patients who were (1)…
- Trial name
- NCT03917537
- Testing
- HNSCC patients have used Nivolumab
- Where
- 2 sites in Taiwan
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Neuroblastoma
Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma
Neuroblastoma, the most common extra-cranial solid tumour in children, remains one of the major challenges in paediatric oncology.
- Trial name
- MiniVan (NCT02914405)
- Testing
- Nivolumab, Ch14.18/CHO
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer
Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood and Primary Tumor in HNSCC/NSCLC/Melanoma
Conventional biopsy and surgical tumor resection are invasive procedures that capture only one instance of the progression of the tumor. However, the genome of tumor is not static, but it is constantly altered during treatment.
- Conditions
- Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma
- Trial name
- NCT04490564
- Testing
- PD-L1 Kit
- Where
- 6 sites in Greece
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Pharmassist Ltd
Muscle Invasive Bladder Urothelial Carcinoma
Drug Screening Using IMD in Bladder Cancer
This research study involves implanting up to 4 microdevices, each small enough to fit inside the tip of a needle, into a tumor.
- Trial name
- NCT06204614
- Testing
- Implantable Micro-Device, Methotrexate, Carboplatin
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma
The choice of the best second-line therapy in patients with high LH R/R risk, it is a niche of knowledge not covered at the moment, especially the role of Brentuximab (BV) plus PD-1 blockade and auto-HSCT.
- Conditions
- Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult
- Trial name
- NCT05595447
- Testing
- Brentuximab Vedotin 50 MG [Adcetris]
- Where
- Mexico
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Hospital Regional de Alta Especialidad del Bajio
Non-Small Cell Carcinoma of Lung, Gut Microbiomes
Microbiota in Neoadjuvant Chemoimmunotherapy for NSCLC
Locally advanced lung cancer (LALC) has poor prognosis despite multimodal therapies. Neoadjuvant chemoimmunotherapy is now standard for resectable stage II-IIIB NSCLC, but patient responses vary.
- Conditions
- Non-Small Cell Carcinoma of Lung, Gut Microbiomes, Neoadjuvant Chemoimmunotherapy
- Trial name
- NCT07752589
- Testing
- Neoadjuvant chemoimmunotherapy
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Guangdong Provincial People's Hospital
Advanced Hepatocellular Carcinoma
Concurrent Nivolumab and External Beam Radiation Therapy for Patients With Advanced HCC
To investigate the efficacy and safety of nivolumab for patients with advanced HCC undergoing EBRT
- Trial name
- Nextrah (NCT04611165)
- Testing
- Nivolumab
- Where
- South Korea
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- National Cancer Center, Korea
Non Small Cell Lung Cancer, Influenza Vaccine
Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors
This project is to assess the immunogenicity, safety and overall survival impact of intramuscular injection of trivalent influenza vaccine in non-small cell lung cancer (NSCLC) patients with PD-1/PD-L1 inhibitor treatment.
- Trial name
- NCT04355806
- Testing
- PD-1/PD-L1 inhibitors, Inactivated trivalent influenza vaccine
- Where
- 2 sites in China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Recurrent or Metastatic Nasopharyngeal Carcinom
Nivolumab Plus Gemcitabine in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma-HN17-11
NPC is a highly chemo-sensitive cancer. Platinum-containing doublet chemotherapy is regarded as the standard treatment for patients with recurrent or metastatic NPC, even though it has never been directly compared with supportive…
- Trial name
- HN17-11 (NCT06440187)
- Testing
- Gemcitabine+ nivolumab
- Where
- South Korea
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Melanoma, Renal Cancer
Microbiome Immunotherapy Toxicity and Response Evaluation
This is a observational study to investigate how the microbiome correlates with efficacy and toxicity of immune checkpoint inhibitors in patients with advanced cancer.
- Conditions
- Melanoma, Renal Cancer, Lung Cancer
- Trial name
- NCT04107168
- Testing
- Nivolumab, Pembrolizumab, Ipilimumab
- Where
- 13 sites in United Kingdom
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- CCTU- Cancer Theme
Melanoma, Ocular Melanoma
Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma
This is an open-label, multi-site, single-arm Phase 2 study of adjuvant nivolumab combined with ipilimumab for the treatment of adult subjects with completely treated high-risk ocular melanoma, as defined in eligibility criteria…
- Trial name
- NCT03528408
- Testing
- Nivolumab, Ipilimumab
- Where
- 6 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Suthee Rapisuwon
Kidney Neoplasms
A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India
The purpose of this study is to assess the safety and efficacy of nivolumab combined with ipilimumab in intermediate and poor-risk participants with previously untreated advanced renal cell carcinoma (RCC) or metastatic RCC…
- Trial name
- CheckMate 7C9 (NCT04513522)
- Testing
- Nivolumab, Ipilimumab
- Where
- 11 sites in India
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Metastatic Triple-negative Breast Cancer
Saci Nivo Rela for TNBC
This is a randomized, open-label, phase Ib study to assess safety and efficacy of sacituzumab govitecan plus nivolumab or sacituzumab govitecan plus a fixed dose combination of nivolumab and relatlimab in patients with any…
- Trial name
- SIMONE (NCT06963905)
- Testing
- Relatlimab FDC + Nivolumab, Sacituzumab Govitecan (SG), Nivolumab
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Yale University
Stage IIIC Skin Melanoma, Stage IV Skin Melanoma
A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases
Nivolumab (OpdivoTM, BMS), a human IgG-4 anti-PD-1 monoclonal antibody has demonstrated anti-tumor activity in patients with advanced melanoma.
- Trial name
- ipniv (NCT02941744)
- Testing
- nivolumab, ipilimumab
- Where
- Belgium
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Universitair Ziekenhuis Brussel